Skip to main content

Table 3 Univariate analysis of metastases-free survival (MFS)

From: Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

 

At 1 year (%)

At 3 years (%)

P

Radiochemotherapy regimen

 Cisplatin weekly (N = 75)

89

68

 

 Cisplatin 100 mg/m2 (N = 58)

83

76

0.66

Age

 ≤56 years (N = 67)

85

71

 

 ≥57 years (N = 66)

88

72

0.30

Gender

 Female (N = 29)

79

69

 

 Male (N = 104)

89

72

0.59

ECOG Performance score

 0–1 (N = 115)

92

79

 

 2 (N = 18)

52

25

<0.001

Primary tumor site

 Oropharynx (N = 69)

89

78

 

 Hypopharynx (N = 19)

71

61

 

 Larynx (N = 30)

100

77

 

 Oral cavity/Floor of mouth (N = 15)

62

44

0.002

T-category

 T1–2 (N = 16)

93

85

 

 T3–4 (N = 117)

85

69

0.93

N-category

 N0-2a (N = 66)

97

81

 

 N2b-3 (N = 67)

76

62

0.001

Histologic grading

 G 1–2 (N = 85)

95

76

 

 G3 (N = 48)

72

63

0.003

Cumulative cisplatin dose

 ≤200 mg/m2 (N = 85)

87

71

 

 >200 mg/m2 (N = 48)

86

73

0.69

  1. After Bonferroni correction for multiple tests, p-values of <0.006 were considered significant
  2. Bold values represent significant p-values
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us